Publications Archive | Page 2 of 2

SITC – 2021 – Poster Presentation 115

An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs […]

Read More… from SITC – 2021 – Poster Presentation 115

SITC – 2021 – Poster Presentation 871

Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia […]

Read More… from SITC – 2021 – Poster Presentation 871

ESGCT – 2021 – Poster Presentation P112

In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]

Read More… from ESGCT – 2021 – Poster Presentation P112

ESGCT – 2021 – Oral Presentation

VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]

Read More… from ESGCT – 2021 – Oral Presentation

ASGCT – 2021 – Oral Presentation

VOR33: A Clinic-Ready CRISPR/Cas9 Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]

Read More… from ASGCT – 2021 – Oral Presentation

ASGCT – 2021 – Poster Presentation 858

Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia […]

Read More… from ASGCT – 2021 – Poster Presentation 858

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies. Li M, Kassim S. Cell & Gene Therapy. 2020 June.

[…]

Read More… from Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies. Li M, Kassim S. Cell & Gene Therapy. 2020 June.

Gene-edited stem cells enable CD-33 directed immune therapy for myeloid malignancies. Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, and Mukherjee S. PNAS. 2019 Mar

[…]

Read More… from Gene-edited stem cells enable CD-33 directed immune therapy for myeloid malignancies. Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, and Mukherjee S. PNAS. 2019 Mar

Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB. Leukemia. 2019 Mar; 33(3):762-808

[…]

Read More… from Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB. Leukemia. 2019 Mar; 33(3):762-808